Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies

被引：0
|
作者：
Rubin, David T. [1 ]
Wolf, Douglas C. [2 ]
Alekseeva, Olga [3 ]
Charles, Lorna [4 ]
Afsari, Sonia [4 ]
Petersen, Ann Katrin [5 ]
Sheffield, James [4 ]
Li, Hongjuan [4 ]
Silva, Diego [4 ]
Lublin, Fred D. [6 ]
Cree, Bruce [7 ]
Cohen, Jeffrey [8 ]
Danese, Silvio [9 ]
机构：
[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA
[2] Atlanta Gastroenterol Associates, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA
[3] Nizhni Novgorod Reg Clin Hosp, Nizhnii Novgorod, Nizhegorod, Russia
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Bristol Myers Squibb, Princeton, CA USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA
[8] Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH USA
[9] Humanitas Clin & Res Ctr IRCCS & Hunimed, Ctr Inflammatory Bowel Dis, Milan, Lombardia, Italy
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S853
引用
收藏
页码：S396 / S396
页数：1
相关论文
共 50 条
  • [41] Low Rate of Infections With Long-term Use of Ozanimod in Relapsing Multiple Sclerosis Trials
    Hartung, Hans-Peter
    Cree, Bruce A. C.
    Selmaj, Krzysztof W.
    Havrdova, Eva Kubala
    Comi, Giancarlo
    Sheffield, James K.
    Minton, Neil
    Janjua, Anne
    Ding, Ning
    Bar-Or, Amit
    NEUROLOGY, 2020, 94 (15)
  • [42] The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
    Shin, S. Shin
    Park, S. J.
    Kim, Y.
    Im, J. P.
    Kim, H. J.
    Lee, K. M.
    Kim, J. W.
    Jung, S. A.
    Lee, J.
    Kang, S. B.
    Shin, S. J.
    Kim, E. S.
    Kim, Y. S.
    Kim, T. O.
    Kim, H. S.
    Park, D. I.
    Kim, H. K.
    Kim, E. S.
    Kim, Y. H.
    Kim, D. H.
    Teng, D.
    Kim, J. H.
    Kim, W. Y.
    Choi, C. H.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S432 - S432
  • [43] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
  • [44] Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results
    Hyams, Jeffrey S.
    O'Brien, Christopher D.
    Padgett, Lakshmi
    Rosh, Joel R.
    Turner, Dan
    Veereman, Genevieve
    Griffiths, Anne M.
    Heyman, Melvin B.
    Wahbeh, Ghassan
    Adedokun, Omoniyi J.
    Strauss, Richard S.
    Lynch, John P.
    Chan, Daphne
    CROHNS & COLITIS 360, 2020, 2 (04) : 1 - 10
  • [45] Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis
    Dubinsky, Marla C.
    Charles, Lorna
    Selmaj, Krzysztof W.
    Comi, Giancarlo
    Krakovich, Anthony
    Rosen, Melissa
    van der Woude, C. Janneke
    Mahadevan, Uma
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (12) : 2512 - 2515
  • [46] Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis
    Dubinsky, Marla C.
    Charles, Lorna
    Selmaj, Krzysztof W.
    Comi, Giancarlo
    Krakovich, Anthony
    van der Woude, C. Janneke
    Mahadevan, Uma
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S887 - S887
  • [47] Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis
    Reinisch, Walter
    Loftus Jr, Edward, V
    Schreiber, Stefan
    Rubin, David T.
    Louis, Edouard
    Hecht, Patrick M.
    Barrachina, Elena Marced
    Kalabic, Jasmina
    Vladea, Ramona
    Sharma, Dolly
    Duan, Weijiang Rachel
    Zhang, Yafei
    Panaccione, Remo
    JOURNAL OF CROHNS & COLITIS, 2025, 19 (04):
  • [48] Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
    Kobayashi, Taku
    Ito, Hiroaki
    Ashida, Toshifumi
    Yokoyama, Tadashi
    Nagahori, Masakazu
    Inaba, Tomoki
    Shikamura, Mitsuhiro
    Yamaguchi, Takayoshi
    Hori, Tetsuharu
    Pinton, Philippe
    Watanabe, Mamoru
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2021, 19 (04) : 448 - +
  • [49] THE EFFICACY AND SAFETY OF ADALIMUMAB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PREDICTORS OF RESPONSE IN KOREA.
    Shin, Seung Yong
    Park, Soo Jung
    Kim, Young
    Im, Jong Pil
    Kim, Hyo-Jong
    Lee, Kang-Moon
    Kim, Ji Won
    Jung, Sung-Ae
    Lee, Jun
    Kang, Sang-Bum
    Shin, Sung Jae
    Kim, Eun Sun
    Kim, You Sun
    Kim, Tae Oh
    Kim, Hyun Soo
    Park, Dongil
    Kim, Hyungkil
    Kim, Eun Soo
    Kim, Dohyun
    Teng, Dennis
    Kim, Jong-Hwa
    Kim, Wonyong
    Choi, Chang Hwan
    GASTROENTEROLOGY, 2020, 158 (06) : S1206 - S1206
  • [50] Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
    Taxonera, Carlos
    Iborra, Marisa
    Maia Bosca-Watts, Marta
    Rubio, Saioa
    Nantes, Oscar
    Higuera, Rebeca
    Bertoletti, Federico
    Martinez-Montiel, Pilar
    Sierra-Ausin, Monica
    Mancenido, Noemi
    Lazar Perez-Calle, Jose
    Algaba, Alicia
    Olivares, David
    Alba, Cristina
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1297 - 1304
12345